+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome



Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome



Antimicrobial Agents and ChemoTherapy 49(9): 3616-3623



The caspofungin clinical trial database offers an opportunity to assess susceptibility results for Candida pathogens obtained from patients with candidiasis and allows for correlations between efficacy outcomes and MICs. Candida isolates have been identified from patients enrolled in four studies of esophageal candidiasis and two studies of invasive candidiasis. The MICs of caspofungin for all baseline isolates were measured at a central laboratory using NCCLS criteria (document M-27A); MICs for caspofungin were defined as the lowest concentration inhibiting prominent growth at 24 h. MICs were then compared to clinical and microbiological outcomes across the two diseases. Susceptibility testing for caspofungin was performed on 515 unique baseline isolates of Candida spp. obtained from patients with esophageal candidiasis. MICs for caspofungin ranged from 0.008 to 4 microg/ml; the MIC50 and MIC90 were 0.5 and 1.0 microg/ml, respectively. Susceptibility testing was also performed on 231 unique baseline isolates of Candida spp. from patients with invasive candidiasis. The majority (approximately 96%) of MICs were between 0.125 and 2 microg/ml, with MIC50 and MIC90 for caspofungin being 0.5 and 2.0 microg/ml, respectively. Overall, caspofungin demonstrated potent in vitro activity against clinical isolates of Candida species. A relationship between MIC for caspofungin and treatment outcome was not seen for patients with either esophageal candidiasis or invasive candidiasis. Patients with isolates for which the MICs were highest (>2 microg/ml) had better outcomes than patients with isolates for which the MICs were lower (<1 microg/ml). Additionally, no correlation between MIC and outcome was identified for specific Candida species.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 004065378

Download citation: RISBibTeXText

PMID: 16127030

DOI: 10.1128/aac.49.9.3616-3623.2005


Related references

Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. European Journal of Clinical Microbiology & Infectious Diseases 22(8): 470-474, 2003

Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis. Pediatric Infectious Disease Journal 36(1): E1-E13, 2017

In vitro susceptibility results and correlation with outcome Results from the randomized invasive candidiasis study of caspofungin vs amphotericin B. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 402, 2002

Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 63(20): 2235-2263, 2003

A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clinical Infectious Diseases 48(12): 1676-1684, 2009

Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility. Antimicrobial Agents and ChemoTherapy 58(1): 229-236, 2014

Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrobial Agents and ChemoTherapy 54(5): 1864-1871, 2010

Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive Candidiasis. Antimicrobial Agents and Chemotherapy 42(1): 129-134, 1998

Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrobial Agents and ChemoTherapy 42(1): 129-134, 1998

Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for the fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrobial Agents & Chemotherapy 42(1): 129-134, 1998

A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana. Medical Mycology 55(6): 686-689, 2017

Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrobial Agents and ChemoTherapy 57(8): 3528-3535, 2013

Pharmacoeconomic Analysis Of Anidulafungin, Micafungin, Caspofungin And Fluconazole In The Treatment Of Candidemia And/Or Invasive Candidiasis In Non-Neutropenic Adult Patients In Spain. Value in Health 18(7): A584-A585, 2015

Caspofungin for the treatment of less common forms of invasive candidiasis. Journal of Antimicrobial ChemoTherapy 60(2): 363-369, 2007

Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. Journal of Acquired Immune Deficiency Syndromes 31(2): 183-187, 2002